Nushama offers Spravato (esketamine) as a safe, FDA-approved, and medically supervised treatment option for adults living with treatment-resistant depression and acute suicidal ideation. Our approach integrates this innovative medicine within a comprehensive, patient-centered care pathway that prioritizes safety, preparation, and integration—the crucial process of translating treatment insights into lasting life changes. For individuals who have tried multiple traditional antidepressants without success, Spravato represents a significant advancement in psychiatric care, offering a novel mechanism of action that can provide rapid relief. At Nushama, we believe this powerful medicine is most effective when administered within a framework of deep therapeutic support, ensuring that its neurobiological benefits are translated into lasting psychological well-being.
Understanding Spravato: A New Approach to Treatment-Resistant Depression
Spravato is a prescription nasal spray containing esketamine, a molecule closely related to ketamine, that has been approved by the U.S. Food and Drug Administration (FDA) for specific mental health conditions. It is indicated for use in adults with treatment-resistant depression (TRD), a condition where individuals have not responded adequately to at least two different oral antidepressant medications. Spravato is always administered in conjunction with a daily oral antidepressant.
In addition to its use for TRD, Janssen Spravato is also approved for treating depressive symptoms in adults who have major depressive disorder (MDD) and are experiencing acute suicidal ideation or behavior. This dual indication makes it a critical tool for providing rapid relief during periods of intense crisis. Unlike traditional treatments that can take weeks or even months to become effective, Spravato is designed to work quickly, offering a new avenue of hope for those navigating the most challenging phases of their mental health journey in 2025.
Mechanism of Action
Spravato works on a completely different neural pathway than conventional antidepressants. Instead of targeting serotonin or norepinephrine, Spravato targets the N-methyl-D-aspartate (NMDA) receptor, a key component of the brain’s glutamatergic system. By modulating this system, esketamine helps restore synaptic connections between brain cells that can be damaged by the long-term effects of stress and depression.
This process fosters a state of enhanced neuroplasticity, which is the brain’s remarkable ability to reorganize its structure and connections. Research has shown that both ketamine and esketamine can rapidly increase the formation of new synapses, essentially helping to rewire the neural circuits implicated in mood and emotional regulation. This rapid synaptogenesis is believed to be the primary driver behind its fast-acting antidepressant effects, offering a biological reset that can lift the weight of severe depression far more quickly than traditional medications.
Clinical Efficacy
The clinical efficacy of Spravato is well-documented in a series of rigorous trials. These studies have consistently demonstrated that Spravato, when used with an oral antidepressant, can produce a statistically significant and rapid improvement in depressive symptoms. One of the most compelling findings is the speed of its effect; some patients begin to show a meaningful response as early as 24 hours after their first dose .
This rapid onset of action is particularly vital for individuals with MDD who are experiencing acute suicidal thoughts. In these crisis situations, the ability to quickly reduce the severity of depressive symptoms can be life-saving. The clinical data supports that Spravato can provide rapid relief from the most debilitating aspects of depression, creating a crucial window of opportunity for individuals to engage more fully in therapy and other supportive treatments aimed at long-term stability and recovery.
Defining Treatment-Resistant Depression (TRD)
Treatment-resistant depression (TRD) is a clinical term used to describe a form of major depressive disorder that does not respond adequately to conventional therapies. TRD is most commonly defined as a depressive episode that has not shown sufficient improvement after trials of at least two different oral antidepressant medications, administered at an adequate dose and for a sufficient duration. Living with TRD is an incredibly challenging experience, often involving a frustrating cycle of different medications with little to no relief. The recognition of TRD as a distinct clinical challenge has spurred the development of innovative treatments like Spravato.
Finding Spravato Treatment at Nushama: Are You a Candidate?
Determining if you are a candidate for Spravato involves a thorough clinical assessment to ensure the treatment is both safe and appropriate for your specific needs. The primary criteria include a formal diagnosis of treatment-resistant depression, confirmed by a documented history of failing to respond to at least two different oral antidepressant treatments. Alternatively, an individual may be eligible if they have a diagnosis of major depressive disorder and are experiencing acute suicidal ideation or behavior.
How to Find a Spravato Treatment Center Near You
Nushama is a certified Spravato treatment center, providing our community with local and convenient access to this groundbreaking therapy. While general resources like the treatment center locator on Spravato.com can provide a list of certified clinics, choosing the right center is a critical decision. When you want to find a Spravato clinic near you that offers more than just the medication, Nushama provides a comprehensive, supportive, and personalized experience. Instead of just being a location on a map, we are a dedicated partner in your wellness journey, offering an environment and clinical model designed specifically for healing.
Why Nushama’s Comprehensive Assessment is Crucial for Eligibility
Our initial screening and assessment process is a critical first step designed to protect your safety and confirm that Spravato is the most suitable treatment for your condition. This comprehensive evaluation is a deep dive into your complete health profile to ensure adherence to the strict criteria set forth by the FDA and the Spravato REMS program. During this assessment, our clinical team will meticulously review your psychiatric and medical history to identify any conditions that may make Spravato treatment unsafe. This rigorous process guarantees that every member who begins a Spravato treatment plan at Nushama is a clinically appropriate candidate.
Collaborative Care Model
Nushama firmly believes in a collaborative and integrated approach to mental healthcare. We see ourselves as a partner in your existing care network and frequently collaborate with referring mental health providers to ensure seamless communication and continuity of care. This partnership ensures that the insights and progress made during your sessions at Nushama can be effectively integrated into your ongoing therapeutic work, creating a robust support system dedicated to your long-term recovery. For clinicians interested in working with us, we have a dedicated pathway for provider referrals and clinical collaboration .
The Nushama Spravato Experience: Safety, Supervision, and Support
The Nushama Spravato experience prioritizes patient safety, comprehensive medical supervision, and dedicated therapeutic support at every stage of treatment. Every aspect of our protocol is designed to meet the highest clinical standards while fostering a sense of trust and comfort for our members.
The Janssen Spravato® REMS Program
Spravato is only available through a mandatory safety program called the Janssen Spravato® REMS (Risk Evaluation and Mitigation Strategy) to manage potential risks like sedation and dissociation. This strict, FDA-required protocol governs how Spravato is prescribed and administered. Under the REMS, Spravato can only be dispensed and administered in a certified healthcare setting, like Nushama, by professionals who have been specially trained on the protocol. This ensures that you receive the medication in a controlled environment where you can be monitored for any adverse effects.
What to Expect During a Session
A Spravato session at Nushama is a structured and closely supervised experience. After settling into a private, calming treatment room, you will self-administer the Spravato nasal spray under the direct observation of a Nushama healthcare professional. Following administration, a mandatory post-dose observation period of approximately two hours begins. During this time, you will relax in our serene, medically monitored environment while our team checks on you periodically.
Spravato Treatment Protocol and Schedule
The Spravato treatment protocol is typically divided into two distinct phases. The journey begins with an induction phase, designed to achieve a rapid reduction in depressive symptoms, which usually involves twice-weekly sessions for the first four weeks. After the induction phase, you will transition to a maintenance phase to sustain your improvements and prevent relapse. The frequency of sessions is gradually reduced based on your individual clinical response, often moving to weekly or bi-weekly sessions.
Safety Protocols and Logistics
Your safety is our paramount concern. Our clinical team is extensively trained to monitor for and manage potential side effects, such as a temporary feeling of dissociation (a sense of detachment), dizziness, or sedation. Due to these potential effects, members are not permitted to drive for the remainder of the day after a Spravato session. You must arrange for a trusted person or a ride-share service to transport you home from our clinic.
Spravato vs. IV Ketamine: Choosing the Best Path for Your Mental Wellness
While both Spravato and IV ketamine are powerful tools for treating depression, they have important differences. Spravato contains esketamine, one molecule from racemic ketamine, and is an FDA-approved nasal spray. Intravenous (IV) infusions use racemic ketamine and are considered an “off-label” use for depression.
Insurance and Accessibility
A major practical difference often comes down to insurance coverage. Because Spravato has specific FDA approval for TRD, it is more likely to be covered by insurance plans. In contrast, IV ketamine therapy is typically not covered, meaning individuals must often pay for the full cost of treatment out-of-pocket.
Personalized Recommendations at Nushama
Nushama is uniquely positioned to help you navigate this choice because we offer both Spravato and IV ketamine treatments. This allows our clinical team to provide a truly unbiased and personalized recommendation based on a comprehensive evaluation of your unique clinical needs, treatment history, and financial considerations. Our goal is to guide you toward the therapeutic path that offers the greatest potential for your healing. You can learn more in our guide to Ketamine vs. Esketamine .
Nushama’s Specialized Approach vs. Hospital-Based Ketamine Programs
When searching for options like “Mayo Clinic ketamine for depression,” individuals are often seeking care from a reputable, research-driven institution. Large hospital systems offer a wide range of services and are at the forefront of medical research, providing a sense of security and trust. While these institutions provide excellent clinical care, their broad focus can sometimes result in a standardized, less personalized patient experience.
Nushama offers a compelling alternative for those seeking a more specialized and intimate approach. We provide a focused, boutique wellness experience specifically designed for psychedelic-assisted therapy. Unlike a large hospital where ketamine may be one of many services, our entire model is purpose-built to support this unique modality. Our specialization allows us to provide a depth of expertise in therapeutic “set and setting” and post-treatment integration that is difficult to achieve in a large-scale system.
A Purpose-Built Therapeutic Environment
At Nushama, we believe the environment is an active and essential component of the treatment itself. We have optimized the therapeutic “set and setting” by providing serene, private treatment rooms instead of standard clinical spaces. Our rooms are designed to be sanctuaries for healing, featuring comfortable seating, soft lighting, and options for curated therapeutic music. This dedicated focus on creating a supportive atmosphere is a core part of our philosophy.
Navigating Your Spravato Journey at Nushama: From Assessment to Integration
Once our comprehensive assessment has confirmed you are an eligible candidate, your formal journey begins with an in-depth consultation to create your personalized treatment plan. This initial session is a crucial part of the preparation process, where we set clear intentions for your healing journey to ensure you enter your first session feeling informed, safe, and empowered.
The Power of Comprehensive Integration Support
Comprehensive integration support is crucial for converting temporary neuroplastic changes from Spravato into lasting behavioral and emotional wellness. Our robust integration framework is a key differentiator and the cornerstone of our approach. We believe integration is the critical bridge that ensures the profound insights gained during treatment do not fade over time. Our clinically trained specialists work with you one-on-one in dedicated sessions to help you process your experiences, make sense of emerging insights, and develop new, healthier patterns of thought and behavior. This dedicated process of turning insights into action is critical for long-term success.
Financial and Insurance Navigation
Nushama’s care team provides dedicated support to help you navigate the financial and insurance aspects of Spravato treatment. We have extensive experience in the verification and pre-authorization process required by many insurance providers. We will work directly with your insurance company to verify your benefits and provide you with complete financial transparency before you begin treatment. Our team can also provide information on potential resources, such as the Janssen CarePath program. Our guide, Is Spravato covered by insurance? , offers further details.
FAQs
Q: What is Spravato and how is it different from traditional antidepressants? A: Spravato (esketamine) is an FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation, working rapidly on the brain’s glutamate system. Unlike traditional antidepressants that primarily target serotonin or norepinephrine and can take weeks to show effects, Spravato often produces symptom improvement within 24 hours.
Q: Is Spravato therapy painful or uncomfortable? A: Spravato administration is generally not painful. Some members may experience temporary side effects like dissociation, dizziness, or sedation. Nushama’s medical team closely monitors you throughout the session and is trained to manage any discomfort.
Q: How long does a Spravato session last, and what should I expect afterwards? A: Each Spravato session involves self-administration of the nasal spray, followed by a mandatory observation period of approximately two hours in our clinic. After the session, you must arrange for a trusted person to drive you home.
Q: Is Spravato covered by insurance? A: Due to its FDA approval, Spravato is often covered by many insurance providers. Nushama’s care team can assist you in verifying your insurance benefits and exploring potential financial assistance programs.
Q: What is the Nushama approach to Spravato treatment? A: At Nushama, our approach is holistic and medically supervised. We combine the evidence-based efficacy of Spravato with comprehensive psychiatric assessments, continuous medical monitoring, and crucial integration support to foster sustainable mental wellness.
